Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin a nephrotoxicity in conscious rats

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 2777-2783

  Nielsen, Finn Thomsen ^a,b   Jensen, Boye L ^a   Marcussen, Niels ^a   Skøtt, Ole ^a   Bie, Peter ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cyclosporin A; Eplerenone; Glomerular filtration rate; Mineralocorticoid receptor antagonist; Nephrotoxicity

Indexed keywords

ALDOSTERONE RECEPTOR; CYCLOSPORIN A; EPLERENONE; HYALIN; MINERALOCORTICOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; REGIONAL BLOOD FLOW; SPIRONOLACTONE;

EID: 58549092050     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn204     Document Type: Article

References (19)

1. Dieperink H, Leyssac PP, Starklint H et al. Long-term cyclosporine nephrotoxicity in the rat: effects on renal function and morphology. Nephrol Dial Transplant 1988; 3: 317-326
2. Iacona A, Rossetti A, Filingeri V et al. Reduced nephrotoxicity and hepatotoxicity in cyclosporine A therapy by enalapril and spironolactone in rats. Drugs Exp Clin Res 1991; 17: 501-506
3. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52
4. McAuley FT, Whiting PH, Thomson AW et al. The influence of enalapril or spironolactone on experimental cyclosporine nephrotoxicity. Biochem Pharmacol 1987; 36: 699-703
5. Pérez-Rojas J, Blanco JA, Cruz C et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292: F131-F139
6. Burgess ED, Lacourciere Y, Ruilope-Urioste LM et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003; 25(9): 2388-2404
7. Dieperink H, Kemp E, Leyssac PP et al. Cyclosporine A: effectiveness and toxicity in a rat model. Clin Nephrol 1986; 25(Suppl 1): S46-S50
8. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800
9. Gabel RA, Ranaei RA, Kivlighn SD. A new method of measuring renal function in conscious rats without the use of radioisotopes. J Pharmacol Toxicol Methods 1996; 36: 189-197
10. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974; 39: 816-825
11. Emmeluth C, Bie P. Effects, release and disposal of endothelin-1 in conscious dogs. Acta Physiol Scand 1992; 146: 197-204
12. Thomsen K, Holstein-Rathlou NH, Leyssac PP. Comparison of three measures of proximal tubular reabsorption: lithium clearance, occlusion time, and micropuncture. Am J Physiol 1981; 241: F348-F355
13. Nielsen FT, Leyssac PP, Kemp E et al. Nephrotoxicity of FK506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nephrol Dial Transplant 1995; 10: 334-340
14. Nielsen FT, Ottosen P, Starklint H et al. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nephrol Dial Transplant 2003; 18: 491-496
15. Chander V, Chopra K. Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine. Ren Fail 2005; 27: 441-450
16. Chander V, Singh D, Tirkey N et al. Amelioration of cyclosporine nephrotoxicity by irbesartan, a selective AT1 receptor antagonist. Ren Fail 2004; 26: 467-477
17. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol 2006; 100: 9-16
18. Shihab FS, Yi H, Bennett WM et al. Effect of nitric oxide modulation on TGF-beta 1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 1174-1185
19. Pérez-Rojas J, Derive S, Blanco JA et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005; 289: 1020-1030